Radius Health Announces Latest 2019 Medicare Part D Coverage for TYMLOS (abaloparatide) Injection

Radius Health (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced the latest 2019 Medicare Part D coverage for TYMLOS which increased to approximately 26.2 million lives or 64% of those enrolled in Medicare Part D plans in the U.S.

As quoted in the press release:

Effective January 1, 2019, SilverScript Insurance Company (a CVS Caremark company), WellCare Health Plans, Inc., and Prime Therapeutics will become the latest Medicare Part D prescription drug plan (PDP) sponsors to cover TYMLOS® (abaloparatide) injection for their beneficiaries. Express Scripts, Inc., UnitedHealthcare (AARP), Kaiser Permanente, and EnvisionRx, among others, have decided to continue Medicare Part D coverage of TYMLOS through 2019.

Over the next couple weeks, payers and PBMs will continue to make publicly available their Medicare Part D 2019 drug formularies. Radius plans to provide a detailed update on TYMLOS’ 2019 formulary coverage at the Company’s Q3 Earnings Call in November.

“I am very happy to have increased our market access for TYMLOS in the Medicare Part D segment and provide our drug to a larger amount of high risk osteoporosis patients who might significantly benefit from treatment with an anabolic drug,” said Jesper Høiland, President and Chief Executive Officer of Radius. “We are very aware of the challenges that high out-of-pocket costs present for patients. One of the reasons TYMLOS is priced approximately 50% less than the other anabolic option is to directly impact the out-of-pocket costs for Medicare Part D patients with a standard Medicare Part D plan.”

Click here to read the full press release.